Literature DB >> 12174733

Prevalence and outcome of partial remission in depression.

Richard Tranter1, Claire O'Donovan, Praful Chandarana, Sidney Kennedy.   

Abstract

The goal of treatment of major depression should be full remission. Many patients, however, fail to achieve or maintain symptom-free status. Residual depressive symptoms are common, even where there has been a robust response to antidepressant therapy. In clinical studies, approximately one-third of patients achieve a full remission, one-third experience a response and one-third are nonresponders. Partial remission is characterized by the presence of poorly defined residual symptoms. These symptoms typically include depressed mood, psychic anxiety, sleep disturbance, fatigue and diminished interest or pleasure. It is currently unclear which factors predict partial remission. However, it is clear that residual symptoms are powerful predictors of relapse, with relapse rates 3-6 times higher in patients with residual symptoms than in those who experience full remission. Residual symptoms are also associated with more medical and psychiatric visits, increased public assistance, disability benefits, thoughts of and attempts at suicide and chronicity. The risk of stroke and coronary events is also higher in patients with residual depressive symptoms. The substantial proportion of patients who achieve only partial remission has traditionally been neglected in antidepressant trials. Given that residual symptoms may relate, in part, to an incompatibility between patient and treatment, further research is needed to predict a better match. These symptoms are a clinically relevant state of illness, and the correct choice of initial antidepressant treatment should offer the greatest chance of achieving full remission.

Entities:  

Mesh:

Year:  2002        PMID: 12174733      PMCID: PMC161658     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  44 in total

1.  Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

Authors:  I M Anderson
Journal:  J Affect Disord       Date:  2000-04       Impact factor: 4.839

2.  Outcome of patients with chronic affective disorder: a five-year follow-up.

Authors:  W Coryell; J Endicott; M Keller
Journal:  Am J Psychiatry       Date:  1990-12       Impact factor: 18.112

3.  Biological markers, treatment outcome, and 1-year follow-up in endogenous depression: electroencephalographic sleep studies and response to cognitive therapy.

Authors:  A D Simons; M E Thase
Journal:  J Consult Clin Psychol       Date:  1992-06

4.  A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

Authors:  M B Keller; J P McCullough; D N Klein; B Arnow; D L Dunner; A J Gelenberg; J C Markowitz; C B Nemeroff; J M Russell; M E Thase; M H Trivedi; J Zajecka
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

5.  Depression, disability days, and days lost from work in a prospective epidemiologic survey.

Authors:  W E Broadhead; D G Blazer; L K George; C K Tse
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

6.  Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

Authors:  E Frank; R F Prien; R B Jarrett; M B Keller; D J Kupfer; P W Lavori; A J Rush; M M Weissman
Journal:  Arch Gen Psychiatry       Date:  1991-09

7.  How effective and safe is continuation therapy in elderly depressed patients? Factors affecting relapse rate.

Authors:  A Georgotas; R E McCue; T B Cooper; N Nagachandran; I Chang
Journal:  Arch Gen Psychiatry       Date:  1988-10

8.  Relapse in major depressive disorder: analysis with the life table.

Authors:  M B Keller; R W Shapiro; P W Lavori; N Wolfe
Journal:  Arch Gen Psychiatry       Date:  1982-08

9.  Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine.

Authors:  R M Hirschfeld; J M Russell; P L Delgado; J Fawcett; R A Friedman; W M Harrison; L M Koran; I W Miller; M E Thase; R H Howland; M A Connolly; R J Miceli
Journal:  J Clin Psychiatry       Date:  1998-12       Impact factor: 4.384

10.  Depressive relapses and incomplete recovery from index episode.

Authors:  C Faravelli; A Ambonetti; S Pallanti; A Pazzagli
Journal:  Am J Psychiatry       Date:  1986-07       Impact factor: 18.112

View more
  28 in total

1.  In the grip of the python: conflicts at the university-industry interface.

Authors:  David Healy
Journal:  Sci Eng Ethics       Date:  2003-01       Impact factor: 3.525

2.  Why treat depression differently from other medical problems?

Authors:  Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

3.  Patterns of depressive symptom remission during the treatment of seasonal affective disorder with cognitive-behavioral therapy or light therapy.

Authors:  Jonah Meyerhoff; Michael A Young; Kelly J Rohan
Journal:  Depress Anxiety       Date:  2018-04-16       Impact factor: 6.505

4.  Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence?

Authors:  Daniel J Taylor; Heather M Walters; Jeffrey R Vittengl; Steven Krebaum; Robin B Jarrett
Journal:  J Affect Disord       Date:  2009-09-05       Impact factor: 4.839

5.  Bouncing back: remission from depression in a 12-year panel study of a representative Canadian community sample.

Authors:  Esme Fuller-Thomson; Marla Battiston; Tahany M Gadalla; Sarah Brennenstuhl
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-01-09       Impact factor: 4.328

Review 6.  [Sleep disorders in depression. Suggestions for a therapeutic approach].

Authors:  C Zimmermann; H Pfeiffer
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 7.  If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.

Authors:  K Ryan Connolly; Michael E Thase
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

8.  Neurocognitive Functioning in Depressed Young People: A Systematic Review and Meta-Analysis.

Authors:  Joanne Goodall; Caroline Fisher; Sarah Hetrick; Lisa Phillips; Emma M Parrish; Kelly Allott
Journal:  Neuropsychol Rev       Date:  2018-04-22       Impact factor: 7.444

Review 9.  Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Guangjian Li; Xu Wang; Dihui Ma
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

10.  Food restriction and streptozotocin differentially modify sensitivity to the hypothermic effects of direct- and indirect-acting serotonin receptor agonists in rats.

Authors:  Jun-Xu Li; Wouter Koek; Charles P France
Journal:  Eur J Pharmacol       Date:  2009-04-18       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.